Cell Bio Human Tech Co.,Ltd
Financials
Valuation Metrics
Cell Bio Human Tech Co.,Ltd's Market Cap is ₩576B. At end of 2025 it was ₩767B. Ranked #1619 of 2,410 in KR market (top 67%), #958 of 1,631 on KOSDAQ (top 59%), #188 of 293 in Materials (top 64%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 57.58B KRW | KR#1,619/2,410 Sec#188/293 |
| Revenue | 60.90B KRW | KR#1,689/2,410 Sec#241/293 |
| Net Income | 10.46B KRW | KR#955/2,410 Sec#110/293 |
| Total Assets | 92.01B KRW | KR#1,846/2,410 Sec#251/293 |
| Net Assets | 63.58B KRW | KR#1,751/2,410 Sec#238/293 |
| Employees | 58 | KR#1,976/2,410 Sec#248/293 |
| Value | ||
| P/E | 5.51x | KR#462/2,410 Sec#58/293 |
| P/B | 0.91x | KR#1,450/2,410 Sec#229/293 |
| PEG | 0.07x | KR#380/2,410 Sec#43/293 |
| P/S | 0.95x | KR#1,405/2,410 Sec#236/293 |
| EV/EBITDA | 6.85x | KR#416/2,410 Sec#48/293 |
| FCF Yield | -8.95% | KR—/2,410 Sec—/293 |
| Profitability | ||
| ROE | 16.45% | KR#259/2,410 Sec#18/293 |
| ROA | 11.37% | KR#213/2,410 Sec#14/293 |
| Op. Margin | 16.05% | KR#266/2,410 Sec#17/293 |
| Revenue Growth | 61.93% | KR#153/2,410 Sec#8/293 |
| Earnings Growth | 76.87% | KR#446/2,410 Sec#51/293 |
| Financial Health | ||
| Debt Ratio | 44.71% | KR#883/2,410 Sec#103/293 |
| Total Debt | 20.42B KRW | KR#1,371/2,410 Sec#210/293 |
| FCF | -5.15B KRW | KR#1,496/2,410 Sec#180/293 |
| Cash | 11.00B KRW | KR#1,638/2,410 Sec#199/293 |
| Current Ratio | 2.87x | KR#589/2,410 Sec#60/293 |
| Net Debt/EBITDA | 0.96x | KR#730/2,410 Sec#72/293 |
| Performance | ||
| 1Y Return | -40.49% | KR#1,744/2,410 Sec#230/293 |
| 1M Return | -8.92% | KR#1,427/2,410 Sec#186/293 |
| From 52W High | -44.58% | KR#933/2,410 Sec#128/293 |
| 1Y MDD | -52.46% | KR#1,060/2,410 Sec#159/293 |
| Trading | ||
| Volume | 9,330 shares | KR#1,608/2,410 Sec#176/293 |
| Trading Value | 57.1M KRW | KR#1,456/2,410 Sec#162/293 |
| Foreign Own. | 4.08% | KR#1,029/2,410 Sec#117/293 |
| Per Share | ||
| EPS | 1,113 KRW | KR#684/2,410 Sec#82/293 |
| BPS | 6,769 KRW | KR#1,282/2,410 Sec#194/293 |
Company Info
CellBioHumanTech was established in 2015 and listed on the KOSDAQ market in 2023. The company develops, manufactures, and supplies mask pack materials such as PT CELL, SEMI GEL, S Cell, and NC Cell, and is expanding into patches and wound dressings. It achieves cost savings and quality enhancement by directly producing non-woven fabrics at its Vietnam local subsidiary. CellBioHumanTech is expanding its global market presence through new material development and pursuing entry into the medical field with wound dressing development. CellBioHumanTech is headquartered in Anyang-si, Gyeonggi-do.